Thromb Haemost 2010; 104(05): 863-866
DOI: 10.1160/TH10-10-0632
Theme Issue Editorial
Schattauer GmbH

Oscar D. Ratnoff: A man for all seasons

Alvin H. Schmaier
1   Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio, USA
› Author Affiliations
Further Information

Publication History

Received: 04 October 2010

Accepted: 04 October 2010

Publication Date:
24 November 2017 (online)

 

 
  • References

  • 1 Saito H. Studies on Fletcher trait and Fitzgerald trait.. Thromb Haemost 2010; 104: 867-874.
  • 2 Hathaway WE, Belhasen LP, Hathaway HS. Evidence for a new plasma thromboplastin factor. 1. Case report, coagulations studies, and physiological properties.. Blood 1965; 26: 521-532.
  • 3 Saito H, Ratnoff OD, Donaldson VH. et al. Fletcher factor deficiency.. Blood 1972; 39: 745-747.
  • 4 Waldmann R, Abraham JP, Rebuck JW. et al. Fitzgerald factor: a hitherto unrecognized coagulation factor.. Lancet 1975; 01: 949-952.
  • 5 Saito H, Ratnoff OD, Waldmann R. et al. Fitzgerald trait: Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface-mediated reactions of clotting, fibrinolysis and generation of kinins and PE/Dil.. J Clin Invest 1975; 55: 1082-1089.
  • 6 Krijanovski Y, Proulle V, Mahdi F. et al. Characterization of molecular defects of Fitzgerald trait and another novel high molecular weight kininogen deficient patient: Insights into structural requirements for kininogen expression.. Blood 2003; 101: 4430-4436.
  • 7 Colman RW, Bagdassarian A, Talamo RC. et al. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways.. J Clin Invest 1975; 56: 1650-1662.
  • 8 Cheung PP, Kinapuli SP, Scott CF. et al. Genetic basis of total kininogen deficiency in Williams’ trait.. J Biol Chem 1993; 268: 23361-23365.
  • 9 Colman RW, Wu Y, Liu Y. Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signaling.. Thromb Haemost 2010; 104: 875-885.
  • 10 Colman RW, Najamunnisa PR, Yan W. et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a sight within domains 2 and 3 of the urokinase receptor.. J Clin Invest 1997; 100: 1481-1487.
  • 11 LaRusch GA, Mahdi F, Shariat-Madar Z. et al. Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis.. Blood 2010; 115: 5111-5120.
  • 12 Schmaier AH, LaRusch G. Factor XII: New life for an old protein.. Thromb Haemost 2010; 104: 915-918.
  • 13 Mahdi F, Shariat-Madar Z, Kuo A. et al. Mapping the interaction between high molecular weight kininogen and the urokinase plasminogen activator receptor.. J Biol Chem 2004; 279: 16621-16628.
  • 14 Schmeidler-Sapiro KT, Ratnoff OD, Gordon EM. Mitogenic effects of coagulation factor XII and factor XIIa on HepG2 cells.. Proc Natl Acad Sci USA 1991; 88: 4382-4385.
  • 15 Renne T, Pozgajova M, Gruner S. et al. Defective thrombus formation in mice lacking coagulation factor XII.. J Exp Med 2005; 202: 271-281.
  • 16 Merkoulov S, Komar AA, Schmaier AH. et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis.. Blood 2008; 111: 1274-1281.
  • 17 van der Meijden PEJ, Munnix IC, Auger JM. et al. Dual role of collagen in factor XII-dependent thrombus formation.. Blood 2009; 114: 881-890.
  • 18 Wilner GD, Nossel HL, LeRoy EC. Activation of Hageman factor by collagen.. J Clin Invest 1968; 47: 2608-2615.
  • 19 Ratnoff OD. Activation of Hageman factor by L-homocystine.. Science 1968; 162: 1007-1009.
  • 20 Greip MA, Fujikawa K, Nelsestuen GL. Possible basis for the apparent surface selectivity of the contact activation of human blood coagulation factor XII.. Biochemistry 1986; 25: 6688-6694.
  • 21 Brower MS, Harpel PC. Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase.. J Biol Chem 1982; 257: 9849-9854.
  • 22 Stief TW, Heimburger N. Inactivation of serine proteinase inhibitors (serpins) in human plasma by reactive oxidants.. Biol Chem Hoppe Seyler 1988; 369: 1337-1342.
  • 23 Chang NS, Boackle RJ, Leu RW. Characterization of C1 inhibitor binding to neutrophils.. Immunology 1991; 73: 95-101.
  • 24 Davis AE III, Lu F, Mejia P. C1 inhibitor, a multi-functional serine protease inhibitor.. Thromb Haemost 2010; 104: 886-893.
  • 25 Ruggeri ZM, Zimmerman TS. Variant von Willebrand’s disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/ von Willebrand factor in plasma and platelets.. J Clin Invest 1980; 65: 1318-1325.
  • 26 Ruggeri Z, Zarpellon A, Roberts JR. et al. Unraveling mechanism and significance of thrombin binding to platelet glycoprotein 1b.. Thromb Haemost 2010; 104: 894-902.
  • 27 Poon M-C, Rand MI, Jackson SC. 2B or not to be – the 45-year saga of the Montreal Platelet syndrome.. Thromb Haemost 2010; 104: 903-910.
  • 28 Milton JG, Frojmovic MM, Tang SS. et al. Spontaneous platelet aggregation in Hereditary Giant Platelet syndrome (MPS).. Am J Path 1984; 114: 336-335.
  • 29 Ruggeri ZM, Pareti FI, Mannucci PM. et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease.. New Engl J Med 1980; 302: 1047-1051.
  • 30 Lederman MM. Haemophilia, human immuno-deficiency virus and human immunodeficiency virus pathgenesis.. Thromb Haemost 2010; 104: 911-914.
  • 31 Lederman MM, Ratnoff OD, Scillian JJ. et al. Impaired cell-mediated immunity in patients with classic haemophilia.. N Engl J Med 1983; 308: 79-83.